Lunai Bioworks Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder Therapeutics
Reuters
Sep 11, 2025
<a href="https://laohu8.com/S/RENB">Lunai Bioworks</a> Subsidiary BioSymetrics and Brigham and Women's Hospital Secure $1.85M NIH STTR Grant to Develop AI-Driven Platform for Alcohol Use Disorder <a href="https://laohu8.com/S/LENZ">Therapeutics</a>
Lunai Bioworks Inc. (NASDAQ:RENB) has announced that its subsidiary, BioSymetrics Inc., in collaboration with Brigham and Women's Hospital, has been awarded a prestigious Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH). The grant, valued at $1.85 million USD, is provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and is aimed at developing an AI-powered platform for drug discovery targeting Alcohol Use Disorder (AUD). This project, co-led by Dr. Calum MacRae from Brigham and Women's Hospital, will utilize AI-driven behavioral phenotyping alongside large-scale drug screening models to address the urgent unmet therapeutic needs of AUD, a condition affecting over 19 million Americans.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1071666) on September 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.